Quantum-si INC 8-K filings

Quantum-Si announced a revised Proteus launch to Q2 2027, impacting its cash runway and leading to a 20% workforce reduction.

Quantum-Si Incorporated received a notice from Nasdaq indicating its common stock has fallen below the $1.00 minimum bid price requirement for continued listing.

Quantum-Si Incorporated has entered into a 10-year lease agreement for a new 54,374 square foot office, laboratory, and manufacturing facility in San Diego, California.

Quantum-Si Incorporated successfully reelected its board of directors and ratified its independent auditor at the 2026 Annual Meeting.

Quantum-Si announced first quarter 2026 results, highlighting successful sequencing on integrated Proteus instruments and continued progress towards commercial launch.

Quantum-Si Incorporated announced its fourth quarter and full year 2025 financial results, revealing a list price for its Proteus platform and providing 2026 financial guidance.

Quantum-Si Incorporated updated the investment community on its business, highlighting the upcoming Proteus platform and its strategic roadmap.

Quantum-Si Incorporated detailed its next-generation Proteus platform, long-term technology roadmap, and plans for a 2026 commercial launch at its Investor & Analyst Day.

Quantum-Si Incorporated announced third quarter 2025 financial results, reporting $552,000 in revenue and successful sequencing on a prototype Proteus system, with the development program remaining on track.

Quantum-Si Incorporated has entered into a sales agreement with Leerink Partners LLC to potentially sell up to $100 million of Class A common stock through an at-the-market offering.

Quantum-Si Incorporated has entered into a Settlement and Mutual Release Agreement to terminate its lease for premises in New Haven, CT, for a total payment of $11 million.

Quantum-Si Incorporated provides an updated corporate presentation detailing its proteomics technology, market strategy, and financial outlook.

Quantum-Si Incorporated announced its second quarter 2025 financial results, reporting increased first-half revenue and a $50 million capital raise, despite experiencing commercial headwinds from NIH funding challenges.

Quantum-Si Incorporated has announced a registered direct offering of common stock and pre-funded warrants, raising approximately $50 million in gross proceeds to advance its Proteus platform and other strategic initiatives.

Quantum-Si Incorporated held its Annual Meeting on May 16, 2025, where shareholders voted on key proposals, including the election of directors and ratification of the company's auditor.

Quantum-Si announces strong Q1 2025 financial results with an 84% revenue increase, the launch of Platinum Pro, and progress in its development programs.

Quantum-Si Incorporated provides an update on its business strategy and future outlook through an updated corporate presentation.

Quantum-Si announces its Q4 and full-year 2024 financial results, highlighted by first quarterly revenue over $1 million and $86 million in capital raises.

Quantum-Si Incorporated has announced a $50 million registered direct offering of common stock to institutional investors, aimed at supporting product development and general corporate needs.

Quantum-Si has entered into an agreement with Canaccord Genuity to sell up to $75 million of its Class A common stock through an at-the-market offering, while simultaneously terminating a similar agreement with Evercore.

Quantum-Si Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price rose above $1.00 per share.

Quantum-Si is implementing a restructuring plan that includes a 23% workforce reduction to streamline operations and focus on product development.

Quantum-Si presented its technology roadmap and advancements in proteomics at its Investor & Analyst Day, highlighting a new platform architecture and expanded capabilities.

Quantum-Si Incorporated received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, putting the company at risk of delisting.

Quantum-Si announced its third quarter 2024 financial results, highlighting revenue of $787,000 and an accelerating sales pipeline, while also noting a lengthening sales cycle impacting full-year revenue guidance.

Quantum-Si Incorporated has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, putting its listing at risk.

Quantum-Si has appointed a new Chief Commercial Officer, Chief Product Officer, and Chief Human Resources Officer to accelerate the company's growth in the proteomic tools market.

Quantum-Si has released an updated corporate presentation detailing its commercial launch, product updates, and financial outlook.

Quantum-Si announced its second quarter 2024 financial results, the launch of a new sequencing kit, and the appointment of a new independent Chairman of the Board.

Quantum-Si provides a corporate update, highlighting the full commercial launch of its Platinum protein sequencing system, the release of its Version 2 kit, and the planned launch of a Version 3 kit.